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Many microbial populations rapidly adapt to changing environments with multiple variants com-
peting for survival. To quantify such complex evolutionary dynamics in vivo, time resolved and
genome wide data including rare variants are essential. We performed whole-genome deep se-
quencing of HIV-1 populations in 9 untreated patients, with 6-12 longitudinal samples per patient
spanning 5-8 years of infection. We show that patterns of minor diversity are reproducible between
patients and mirror global HIV-1 diversity, suggesting a universal landscape of fitness costs that
control diversity. Reversions towards the ancestral HIV-1 sequence are observed throughout in-
fection and account for almost one third of all sequence changes. Reversion rates depend strongly
on conservation. Frequent recombination limits linkage disequilibrium to about 100bp in most of
the genome, but strong hitch-hiking due to short range linkage limits diversity.
The human immunodeficiency virus 1 (HIV-1) is a
paradigmatic example of a rapidly adapting popula-
tion characterized by high diversity, strong selection,
and recombination. HIV-1 has originated from multi-
ple zoonotic transmissions from apes in the early part of
the 20th century (Sharp and Hahn, 2011), one of which
gave rise to the worldwide pandemic. This lineage is
called group M and has diversified into different sub-
types at a rate of about 1 in 1000 substitutions per year
(Lemey et al., 2005; Li et al., 2015). This diversifica-
tion has been extensively characterized and sequences of
tens of thousand of HIV-1 variants are available in the
Los Alamos National Laboratories HIV database (LANL)
(Foley et al., 2013).
The evolution of HIV-1 ultimately takes place within
infected individuals and can be observed directly in longi-
tudinal samples of virus populations from the same indi-
vidual. The detailed knowledge of HIV-1 biology paired
with historical samples make HIV-1 an ideal system to
study general features of evolution at high mutation rates
and strong selection that are otherwise only accessible in
evolution experiments (Elena and Lenski, 2003; Miralles
et al., 1999).
Longitudinal data has been used to characterize escape
from cytotoxic T-cells (CTL) (Kearney et al., 2009; Liu
et al., 2011; Salazar-Gonzalez et al., 2009), track evo-
lution driven by the humoral immune response against
HIV-1 (Richman et al., 2003; Shankarappa et al., 1999)
and to study the emergence of drug resistance (Pare-
des et al., 2009). In a pioneering study, Shankarappa
et al. (1999) characterized HIV-1 evolution of parts of the
gp120 envelope protein over approximately 6-12 years in
11 patients, demonstrating consistent evolution of diver-
sity and divergence. While this early study was limited
to about 10 sequences per sample, next-generation se-
quencing technology today allows deep characterization
of intrapatient HIV-1 variability including rare mutations
(Fischer et al., 2010; Hedskog et al., 2010; Tsibris et al.,
2009). However, these studies had limited follow-up (i.e.
only one or a few time points were sequenced) or focused
on small parts of the genome. Henn et al. (2012) was the
first study to sequence the majority of the virus genome,
but is restricted to a single patient with limited follow-up.
To develop a comprehensive and quantitative under-
standing of the evolution and diversification of HIV-
1 populations, we generated a whole-genome, deep-
sequencing data set covering 9 patients over 5 to 8 years
with 6 to 12 time points per patient. Importantly, the
data set covers the entire genome such that no substi-
tution is missed and includes early samples defining the
initial population. To our knowledge, this is the only
whole-genome deep sequencing data set with long follow-
up of multiple patients.
Below, we first describe the methodology we developed
to sequence the entire HIV-1 genome at a great depth
while preserving linkage over several hundred base pairs.
We then analyze the intrapatient evolution of HIV-1 and
show that the minor variants in the virus population ex-
plore sequence space in predictable fashion at the single
site level. At the same time, we observe a strong ten-
dency for reversion towards the global HIV-1 consensus.
Reversion is faster at sites that are more conserved at the
global level – suggesting a direct relationship between in-
trapatient fitness cost and global conservation. We fur-
ther find frequent recombination, which allows the viral
population to evolve independently in different regions of
the genome. Nevertheless, recombination is not frequent
enough to decouple mutations closer than 100 base pairs
and we observe signatures of hitch-hiking at short dis-
tances (Maynard Smith and Haigh, 1974).
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The study included nine HIV-1-infected patients who
were diagnosed in Sweden between 1990 and 2003. Data
from two additional patients were excluded from analysis
because of suspected superinfection and failure to amplify
early samples with low virus levels, respectively. The pa-
tients were selected to have a relatively well-defined time
of infection and have been treatment-naive for a mini-
mum of five years. Patients diagnosed in recent years
rarely fulfill these inclusion criteria because therapy is al-
most universally recommended, but this was not the case
when the study patients were diagnosed. Basic charac-
teristics of the patients and the samples are presented
in Table I. The method to estimate the time since infec-
tion (ETI) is described in Materials and Methods. Of
the nine patients, eight were males, seven were men who
have sex with men (MSM), two were heterosexually in-
fected (HET), and eight were infected in Sweden. We
retrieved longitudinal biobank plasma samples covering
the time period during which the patients had been un-
treated (5.5-8.3 years). The number of samples per pa-
tient ranged between 6 and 12 and in total we investi-
gated 73 samples. The median plasma HIV-1 RNA level
was 12,000 copies/ml for the samples with available data
on RNA levels. Some samples had low RNA levels, which
partly is explained by the study design that required that
the patients were treatment-naive for at least five years.
For detailed information about each individual sample
see supplementary table S1 (S1_samples.csv).
HIV-1 whole-genome deep sequencing
We extracted viral RNA and amplified and sequenced
it as explained in Materials and Methods. The basic
steps are illustrated in Figure 1. Viral RNA was ex-
tracted from 400 µl patient plasma and used for one-step
RT-PCR amplification with six overlapping primer sets
that span almost the complete HIV-1 genome, similar to
the strategy developed by Gall et al. (2012). Sequencing
libraries were made starting from 0.1 – 1.5 ng of DNA
with a stringent size selection for long inserts (>400 bp);
the sequencing reads were filtered and mapped to the
individual fragments defined by the PCR primers. Se-
quencing was performed on the Illumina MiSeq platform
and sequence reads were quality filtered and assembled
using an in-house data processing pipeline (see Materials
and Methods). In total approximately 100 million reads
passed the quality filtering. The coverage varied consid-
erably between samples and amplicons, but was mostly
of the order of several thousands or more, see Figure 1B.
Importantly, sequencing depth is determined not only
by coverage but also by template availability and se-
quencing errors. We performed a number of control ex-
periments to quantify templates and assess the accuracy
of estimates of frequencies of SNP. The results are sum-
marized in the following section and described in detail
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Figure 1 Sequencing, coverage, and error rates. (A)
schematics of the sample preparation protocol, see text and
Materials and Methods for details. (B) Read coverage for a
representative sample. Coverage of separate PCR amplicons
is shown in different hues, the black line is the total coverage.
The coverage of PCR fragment F5 is lower than the other
amplicons, but it is still larger than number of input HIV-1
RNA molecules; this situation is typical in our samples. (C)
Each blue circle corresponds to a SNP frequency in amplicon
F1 of a late sample of patient 11, while red squares are SNP
frequencies in the sequence data generated from 10,000 copies
of plasmid NL4-3. The histogram on the right shows the
distribution of SNP frequencies in the patient sample and the
control. Minor SNPs observed in reads generated from the
plasmid, which represent PCR and sequencing errors, did not
exceed 0.3%.
in Materials and Methods.
We quantified the number of HIV-1 genomes that con-
tributed to each sequencing library by PCR limiting dilu-
tion. Comparison with routine plasma HIV-1 RNA level
measurements performed at time of sampling showed
that the median template cDNA recovery efficiency was
30%. Most samples had low to moderate HIV-1 RNA lev-
els and hence template availability, rather than coverage,
3Patient Gender Transmission Subtype Age* Fiebig BED* No. of First sample Last sample HLA type
route [years] stage* [ODn] samples [days] [years] A B C
p1 F HET 01_AE 37 IV 0.41 12 49 8.0 02/02 08/15 03/06
p2 M MSM B 32 V 0.17 6 74 5.5 01/24 08/39 07/12
p3 M MSM B 52 VI 0.89 10 104 8.3 02/11 15/44 03/16
p5 M MSM B 38 III-IV n.a. 7 132 5.9 03/33 14/58 03/08
p6 M HET C 31 IV 0.29 7 46 7.0 02/02 44/51 05/16
p8 M MSM B 35 V 0.15 7 64 6.0 03/32 07/40 02/07
p9 M MSM B 32 VI 0.27 8 106 8.1 25/32 07/44 04/07
p10 M MSM B 34 II 0.10 9 18 6.1 32/32 44/50 06/16
p11 M MSM B 53 VI 1.22 7 167 5.5 02/32 39/44 05/12
Table I Summary of patient characteristics. Sample times from estimated date of infection. ∗, at base line; MSM, men who
have sex with men; HET, heterosexual.
determined the sequencing depth, see Figure 1B.
We estimated the error rate of the PCR and sequencing
pipeline by amplifying and sequencing a plasmid clone.
Figure 1C compares the SNP frequencies observed in a
clone to those observed in a patient sample. After qual-
ity filtering, PCR and sequencing errors never exceeded
0.3% of reads covering a particular position. To detect
and control for variation in PCR efficiency among frag-
ments and skewed amplification of different variants, we
compared frequencies of variants in overlaps between the
six amplicons. A SNP in the overlap is amplified and
sequenced twice independently and the concordance of
the two measurements of variant frequencies was used to
estimate the fragment specific depth, see Materials and
Methods and Figure 9. Frequency estimates were often
reproducible to within 1%. Sometimes, however, variant
recovery was poor (mostly in fragment 5) and frequency
estimates less accurate.
We minimized PCR recombination by reducing the
number of PCR cycles and optimizing the reaction pro-
tocol (see Materials and Methods, Di Giallonardo et al.
(2013); Mild et al. (2011)). Control experiments using
mixtures of two cultured virus populations show that less
than 10% of reads have experienced RT-PCR recombina-
tion.
Taken together, our control experiments show that de-
pending on the sample and fragment, we could estimate
frequencies of SNPs down to 1% accuracy (corresponding
to several thousand effective templates). In some cases,
however, the template number was low or template re-
covery poor such that only presence or absence of a vari-
ant could be called. Furthermore, SNPs remained linked
through PCR and sequencing.
Consistent evolution across the entire genome
In most patients, the virus populations was initially
homogeneous and diversified over the years, as expected
for an infection with a single or small number of similar
founder viruses (Keele et al., 2008). In two patients, p3
and p10, the first sample displayed diversity consistent
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Figure 2 The dynamics of SNP frequencies. The upper
panels show single nucleotide polymorphism frequencies along
p17 at three time points in patient p1. The lower panel shows
the trajectories of SNPs through time. Color corresponds to
position in the sequence. Trajectory that reach high frequen-
cies are shown with thicker and more opaque lines. Analogous
data is available for all patients for most of the HIV-1 genome.
with the transmission of several variants from the same
donor. For each of the nine patients we reconstructed
the HIV-1 genome sequence of the first sample by an
iterative mapping procedure described in Materials and
Methods. This initial consensus sequence approximates
the sequence of the founder virus(es).
Figure 2 shows an example of the dynamics of fre-
quencies of SNP relative to the founder sequence over
time, where each dot (top) or line (bottom) represents
the frequency of a nucleotide different from the founder
sequence. Interactive versions of this graph are available
for the entire genome of all patients at hiv.tuebingen.
mpg.de.
To measure the rate at which the virus population ac-
cumulates mutations, we calculated the average distance
of each sample from the founder sequence in 300bp win-
dows. Regressing this divergence against time yields the
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Figure 3 Consistent evolution across the viral genome.
The figure shows the rate of sequence divergence averaged
in a sliding window of length 300 bp for individual study
participants (in color) and averaged over all (black). Rapidly
evolving (V loops in gp120) and conserved (RRE) regions are
readily apparent. The divergence rates are determined by
linear regression of the distance from the putative founder
sequence against ETI. This distance includes contributions of
minor variants. All positions are given in HxB2 numbering.
rate of divergence in different regions of the genome, see
Figure 3. As expected, some regions such as the vari-
able loops in gp120 and nef evolve faster, while enzymes
– protease (PR), reverse transcriptase (RT) – and the
rev response element (RRE) evolve more slowly. The
rate of divergence varies by about a factor of 10 along
the genome, but it is consistent with typically about
1.5-fold differences across patients (standard deviation
of log2(fold change) 0.6 ± 0.2). The overall pattern of
the rate of mutation accumulation agrees with a recent
map of HIV genome-wide variation from a population
perspective (Li et al., 2015) and correlates well with en-
tropy in a large HIV-1 group M alignment (Spearman’s
ρ = 0.7 after the same smoothing).
Minor variants reproducibly explore global HIV-1 diversity
Having found that coarse patterns of divergence are
comparable among patients, we asked whether intrap-
atient diversity at individual sites in the viral genome
follows general and predictable patterns. To this end,
we compared diversity at each position to the diversity
observed in HIV-1 group M (see Materials and Methods).
Figure 4A shows the rank correlation between the site-
by-site diversity in each patient and a global collection
of HIV-1 sequences, both measured by Shannon entropy
(see Materials and Methods). In all cases correlation with
cross-sectional diversity was initially low, as expected for
largely homogeneous populations. As diversity increases
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Figure 4 Within patient variation mirrors global vari-
ation. (A) Intrapatient variation at individual sites is corre-
lated with diversity at homologous positions in an alignment
of sequences representative of HIV-1 group M. This corre-
lation increases reproducibly throughout the infection. Error
bars show standard deviations over genomic regions. (B) Sim-
ilarly, the fraction of sites with minor variants above 1% in-
creases over time at the least constrained positions (quartiles
Q3 and Q4), while few sites in the most conserved quartiles
(Q1 and Q2) are polymorphic.
within patients, it tends to accumulate at positions that
are not conserved, resulting in a rank correlation of about
0.4-0.5 after about 8 years. These correlations are in-
dividually significant and reproducible among different
genomic regions (error bars in Figure 4).
Figure 4B offers an alternative perspective on the ex-
ploration of sequence space by the HIV-1 populations.
We classified nucleotide positions in the genome into four
categories ranging from highly conserved positions to less
conserved positions within group M (Q1 - Q4) using the
same alignment as above. Next we asked what fraction
of sites within these categories show intrapatient varia-
tion at a level of at least 1%. For the least conserved
positions, this fraction increased steadily to about 20%
after 8 years, while less than 1% of the most conserved
sites shows variation at the 1% level. This latter fraction
rapidly saturates and does not increase over time. Since
variant amplification, sequencing and variant calling does
not use any information on cross-sectional conservations,
the absence of variation above 1% at conserved sites
is further evidence that our amplification and sequenc-
ing pipeline does not generate spurious variation. Other
thresholds yield similar results.
Taken together, the observations in Figure 4 show that
variation is not limited by the mutational input, but
that HIV-1 populations accumulate diversity wherever
mutations do not severely compromise virus replication.
At the single nucleotide level, the spectrum of muta-
tional possibilities is explored reproducibly and the level
of within-host diversity is predicted by time since infec-
tion and cross-sectional diversity. Conserved positions
are typically monomorphic even in deep samples.
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Figure 5 Distinct patterns of evolution across muta-
tion types and regions. Panel A shows divergence at non-
synonymous (solid) and synonymous (dashed) positions over
time for different genomic regions averaged over all patients.
While synonymous divergence is very similar in different re-
gions, nonsynonynous divergence varies. Panel B shows diver-
sity though time. Regions with high nonsynonymous diversity
(and divergence) tend to have low synonymous diversity. Er-
ror bars represent standard deviations of patient bootstrap
replicates. Panel C shows the anti-correlation between the
rate of nonsynonymous divergence and synonymous diversity
in 1kb windows across the genome (color indicates position
on the genome blue→green→yellow→red). Panel D shows
the site frequency spectrum of synonymous (blue) and non-
synonymous (green) SNPs.
The majority of nonsynonymous substitutions are positively
selected
In addition to the reproducible patterns of minor di-
versity, virus evolution is characterized by adaptations
that are specific to the host. Immune selection results in
escape mutations that rapidly spread through the pop-
ulation (Richman et al., 2003; Walker and McMichael,
2012). Such mutations tend to be nonsynonymous, i.e.,
change the viral proteins, while evolution at synonymous
sites is expected to be conservative. Nevertheless, syn-
onymous mutations are affected by “selective sweeps” of
linked nonsynonymous mutations (Maynard Smith and
Haigh, 1974).
To quantify the degree at which the evolutionary dy-
namics of HIV-1 is dominated by selective sweeps, we
calculated divergence and diversity separately nonsyn-
onymous and synonymous in different parts of the HIV-
1 genome. Figure 5A compares nonsynonymous (solid
lines) and synonymous divergence (dashed lines) in differ-
ent regions of the genome. In agreement with the results
presented in Figure 3, the observed rate of evolution at
nonsynonymous sites differed substantially between ge-
nomic regions, with env being fastest and pol slowest.
Divergence at synonymous sites, however, varies very lit-
tle between different genomic regions indicating random
accumulation of synonymous mutations (rather than pos-
itive selection).
Figure 5B shows the corresponding plot for diversity,
i.e., the distances between sequences from the same sam-
ple. Diversity at nonsynonymous sites (solid lines) satu-
rates after about 2-4 years, suggesting that nonsynony-
mous SNPs either stay at low frequency because they
are deleterious, or rapidly increase in frequency and fix
without contributing much to diversity. Synonymous di-
versity increases steadily in the 5’ part of the genome
(structural and enzymes), while it saturates in the 3’ half
of the genome after a few years – the exact opposite of
nonsynonymous divergence.
Indeed, we observe a strong anti-correlation between
synonymous diversity and nonsynonymous divergence,
which is further quantified in Figure 5C. This suggests
that frequent non-synonymous substitutions limit syn-
onymous because they drive linked synonymous muta-
tions to fixation or to extinction (Maynard Smith and
Haigh, 1974). We will quantify linkage and recombina-
tion below, but the differences in diversity accumulation
already suggest that linkage is restricted to short dis-
tances.
The contrasting behavior of synonymous and nonsyn-
onymous SNPs is also seen in the SNP frequency spec-
trum – the histogram of SNP abundance – shown in
Figure 5D. While the spectra agree for frequencies be-
low 20%, synonymous mutations are strongly under-
represented at higher frequencies (Fisher’s exact test
at frequency 0.5, p-value ∼ 10−80). This corroborates
the interpretation that due to substantial recombina-
tion, sweeping nonsynonymous mutations only occasion-
ally “drag” adjacent synonymous mutations to fixation.
Synonymous mutations rarely rise in frequency because
of their own effect on fitness, since they usually have
small or deleterious phenotypic effects and do not con-
tribute directly in immune evasion (Zanini and Neher,
2013). The about 5-fold excess of nonsynonymous over
synonymous SNPs at high frequencies (see Figure 5D)
shows that the majority of common nonsynonymous mu-
tations spread due to positive selection.
Next, we sought to quantify what fraction of nonsyn-
onymous divergence is driven by escape from cytotoxic
T-lymphocytes (CTLs). Four-digit HLA types were de-
termined for all patients and a set of putatively targeted
HIV-1 epitopes were determined using the epitope bind-
ing prediction tool MHCi (tools.immuneepitope.org/
mhci). We then asked whether we observed more non-
synonymous substitutions in epitopes predicted to be tar-
geted than expected by chance (excluding the variable
loops of gp120 and the external part of gp41, see Mate-
rials and Methods). We found a significant enrichment
60 1 2 3 4 5 6 7
ETI [years]
0.00
0.04
0.08
0.12
D
iv
er
ge
nc
e 
fr
om
 fo
un
de
r
A
founder = subtype
founder   subtype
founder = group M
founder   group M
10­2 10­1 100
Variability [bits]
10­4
10­3
10­2
10­1
100
D
iv
er
ge
nc
e 
fr
om
 fo
un
de
r
B
Figure 6 Rapid reversion at conserved sites. Panel A:
Sites where the founder sequence differed from the subtype
or group M consensus (upper curves) diverged about 10 fold
more rapidly than sites that initially agreed with the consen-
sus (lower curves). Panel B: The rate of reversion increased
with conservation (lower variability), while divergence away
from consensus showed the opposite behavior (divergence is
measured at 5-6 years). Error bars report the standard devi-
ation of patient bootstraps.
by a factor 1.9 in the putatively targeted region (p-value
< 3×10−6), corresponding to 5.5 excess nonsynonymous
substitutions, whereby the total number of nonsynony-
mous substitutions per patient is on average 43 (median,
quartiles 36 – 64). Note that the set of predicted epitopes
will contain false positives and lack true epitopes, hence
the actual number of CTL driven substitutions could be
higher as for example suggested by Allen et al. (2005)
who report that roughly half of non-envelope mutations
are associated with CTL responses.
Extensive reversion towards consensus
Many CTL escape mutations reduce the replicative ca-
pacity of the virus and it is known that such escape mu-
tations often revert upon transmission to a host in which
the corresponding epitope is not targeted (Friedrich
et al., 2004; Herbeck et al., 2006; Leslie et al., 2004).
The balance between escape and reversion results in as-
sociation between specific escape mutations and the HLA
types of the hosts (Kawashima et al., 2009; Palmer et al.,
2013). In a large population of hosts, the most common
allele at a specific site is likely favored, while rare alleles
tend to be escape mutations that reduce viral replicative
capacity (Carlson et al., 2014).
To quantify patterns of reversion and fitness cost, we
classified sites in the approximate founder sequence of
the viral populations in each subject as being identical or
different from the HIV-1 group M consensus. Figure 6A
shows the fraction of sites where the founder nucleotide is
replaced by a mutant during the infection. This fraction
is about 10 fold higher if the founder nucleotide differs
from the group M consensus than if it is identical to the
group M consensus. Reversion towards group M con-
sensus occurs at a roughly constant rate throughout the
observation time (5-8 years).
Of all changes accumulated by the viral populations,
30 ± 2.5% are reversions towards group M consensus
(mean and standard deviation of patient bootstraps after
4-7 years). Similar results are found when comparing to
the subtype consensus of each patient virus (24± 2.5%).
Reversions are between 4 and 5 times more frequent than
expected in absence of a reversion bias (7.8% and 4.5%,
respectively). These findings agree with results by Allen
et al. (2005), who report that about 20% of amino acid
substitutions are reversions.
By focusing on sites where the founder virus differed
from the group M consensus, we are predominantly look-
ing at weakly conserved sites. To control for conserva-
tion, we carried out the same analysis after stratifying
sites by overall level of conservation. Figure 6B shows the
result of this analysis, focusing on samples after 5-6 years
for the sake of clarity. We find that the rate of reversion
is highest at the most conserved sites. Almost 50% of
all non-consensus positions at highly conserved sites had
reverted to consensus after about 5 years – an almost
1000-fold excess. Even at the least conserved sites, di-
vergence towards group M consensus exceeded divergence
away from group M consensus by a factor of 3. These re-
sults suggest that the global HIV-1 group M consensus
sequence represents an “optimal” HIV-1 sequence, which
acts as an attractor for the evolutionary dynamics within
hosts. This attraction is strongest at conserved sites, but
extends to the least conserved sites in the genome.
Lack of long-range linkage due to frequent recombination
To quantify the decoupling of SNPs by recombination,
we calculated linkage disequilibrium (LD) between SNPs
as a function of distance for each of the six fragments, see
Figure 7. For most fragments, we observed a consistent
decrease of LD over the first 100-200 bps, with fragment
5 being an exception with linkage of mutations at longer
distances. Importantly, our linkage control (a 50/50 mix
of two distinct virus isolates and a total of 1,250 RNA
molecules per PCR fragment) shows no decay of LD with
distance at all, suggesting negligible RT-PCR recombina-
tion.
The observed decay of LD in patient samples is con-
sistent with a recombination rate of 10−5/bp/day as es-
timated in (Batorsky et al., 2011; Neher and Leitner,
2010). Our reasoning proceeds as follows. Figure 6B
indicates that diversity accumulates over a time frame of
2-4 years, i.e., about 1,000 days. Recombination at a rate
of 10−5/bp/day hits a genome on average every 100 bps
in 1000 days. Mutations further apart than 100bps are
hence often separated by recombination and retain little
linkage consistent with the observed decay length in Fig-
ure 7. The longer linkage in fragment 5 (env) might have
several reasons that extend beyond our simple argument:
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Figure 7 Linkage and recombination. Linkage disequi-
librium decays rapidly with distance between SNPs. Colored
lines correspond to the different fragments, each averaged over
patients. The dashed line shows data from a control experi-
ment for PCR recombination, where two cultured virus pop-
ulations were mixed. No PCR recombination is observed.
(i) homologous recombination might be suppressed in the
most variable regions, (ii) the accuracy of SNP frequency
estimates is lower in F5 due to poorer amplification, and
(iii) the rapid evolution of env due frequent substitutions
and sweeps gives less time to break up linkage. In partic-
ular, as shown in Figure 5C, frequent and strong selective
sweeps affect synonymous diversity in physical proximity
along the genome, confirming the presence of linkage at
short distances.
For phylogenetic analysis, we can extract haplotypes
from the sequencing reads up to 500bp in length. Only
in the more diverse regions are 500bp sufficient for well
resolved phylogenies (see Figure 8). However, we find
that linkage does not extend beyond 100-200bp. Hence
the read length is not a limiting factor. Only during rapid
population shifts such as drug resistance evolution, long
read technologies such as PacBio would be necessary to
capture the evolutionary dynamics (Nijhuis et al., 1998).
Discussion
We have presented a comprehensive portrait of intra-
patient evolution of HIV-1 that covers almost the entire
genome of the virus, characterizes minor genetic variants,
and tracks the fate and dynamics of these variants over
a follow-up period of up to 8 years in 9 patients. We find
that during the infection HIV-1 explores the sequence
space surrounding the founder virus systematically; simi-
lar mutational patterns are observed within different, un-
related patients. Linkage between mutations is limited to
approximately 100bp, so the virus population can accu-
Figure 8 Phylogenetic trees of minor genetic variants.
In rapidly evolving genomic regions, trees that include minor
genetic variants (haplotypes) approximate the true phylogeny.
Here p17 in gag and the variable loop 3 in env from patient p1
are compared. Trees are reconstructed using FastTree (Price
et al., 2009).
mulate substitutions independently in different regions of
the genome as suggested by theoretical models (Mostowy
et al., 2011; Rouzine and Coffin, 2005). Nonetheless, lo-
cal dynamics of SNPs is often dominated by hitch-hiking
between neighboring mutations, resulting in an anticor-
relation between nonsynonymous divergence and synony-
mous diversity. A large fraction of all substitutions are
reversions towards the global HIV-1 consensus sequence,
and these reversions steadily accumulate throughout in-
fection.
The evolutionary dynamics of HIV-1 populations is the
result of stochastic forces like mutation and frequent bot-
tlenecks, deterministic fixation of favorable mutations,
and recombination. The relative importance of these
forces remains unclear (Brown, 1997; Frost et al., 2000;
Kouyos et al., 2006; Maldarelli et al., 2013; Pennings
et al., 2014; Rouzine and Coffin, 1999). Our observation
that intrapatient diversity recapitulates diversity seen
across HIV-1 group M and the strong tendency to revert
towards consensus suggest that in chronic infection selec-
tion determines diversity. The reproducible exploration
of sequence space can coexist with frequent adaptation
only in frequently recombining large populations (Neher
et al., 2013). We observe that mutations further apart
than 100 bp are effectively shuffled by recombination in
most parts of genome, consistent with previous estimates
of the HIV-1 recombination rate (Batorsky et al., 2011;
Neher and Leitner, 2010). Linkage and stochastic effects
become stronger with increasing frequency of strength
of selection, consistent with lower synonymous diversity
and more LD in env .
While rapid CTL escape at 5-10 sites over the first two
years of infection has been documented in detail (Allen
et al., 2005; Herbeck et al., 2006; Liu et al., 2011; Salazar-
Gonzalez et al., 2009) and population level associations
8between specific HLA types and escape variants suggest
widespread CTL escape (Kawashima et al., 2009), the
effect of escape and reversion on long-term evolutionary
trends is less clear (Lythgoe and Fraser, 2012; Roberts
et al., 2015). We find a strong tendency for viral pop-
ulations to revert towards the global HIV-1 consensus.
At sites where the founder sequence differs from the sub-
type consensus, substitutions are almost 5-fold overrep-
resented: Instead of ≈ 5% reversions expected based on
the fraction of sequence at which the founder virus dif-
fers from consensus of the HIV-1 subtype, almost 25% of
substitutions are reversions, in agreement with earlier re-
ports on reversion of CTL escapes (Allen et al., 2005; Li
et al., 2007). This tendency to revert increases with the
level of conservation of the site, suggesting a quantitative
relationship between fitness cost and conservation. While
reversion is particularly prevalent in acute infection (Li
et al., 2007), we show that reversion is not limited to early
infection but happens throughout chronic infection.
The bias towards reversion results in a two to three
fold reduction of the long-term evolutionary rate of HIV,
a trend that is reinforced by selection during transmission
(Carlson et al., 2014; Sagar et al., 2009). Inter-individual
evolutionary rates of HIV-1 are two to six times lower
than intra-individual rates, and a number of possible
mechanisms have been suggested to explain this discrep-
ancy (Lythgoe and Fraser, 2012). Our results strongly
indicate that most of this mismatch can be explained by
steady reversion during infection; other factors such as
retrieval of “stored” latent variants or stage-specific se-
lection might also contribute to the rate mismatch (Im-
monen and Leitner, 2014; Lythgoe and Fraser, 2012).
The high rate of reversion has implications for phylo-
genetic dating. Given the 5-fold excess of reverting mi-
nor variation, reversion would balance divergence once
the typical distance from the consensus sequence equals
17%, corresponding to a nucleotide diversity of about
30%; this is remarkably close to the actual divergence
between HIV-1 groups M, N and O (Li et al., 2015).
On longer distances, this simple argument will have to
be modified due to compensatory mutations resulting in
gradual shift of the preferred state at some positions;
nonetheless, it indicates a dramatic slowing down of di-
vergence at a scale of the HIV-1-SIVcpz divergence. This
apparent deceleration of evolution could explain the con-
tradictory findings of attempts to date the age of HIV-1
and SIV (Worobey et al., 2010). The strong and lasting
preference for specific nucleotides needs to be accounted
for in phylogenetic analysis, as has recently been shown
using experimentally determined fitness landscapes of in-
fluenza virus proteins (Bloom, 2014).
The concordance between intrahost variation and pat-
terns of conservation across HIV-1 group M hints at uni-
versal fitness costs of mutations. Recently, cross-sectional
conservation has been used as a proxy for fitness costs
in models of HIV-1 fitness landscapes (Ferguson et al.,
2013). Since reproducible intrapatient diversity likely re-
flects fitness costs of mutations in vivo, our results pro-
vide a direct justification for this approach. However, 9
patients are insufficient to extend this analysis to fitness
interactions between mutations.
One limitation of this study was the availability of sam-
ples from patients with sufficiently long follow-up with-
out therapy after a well-defined time of infection. The
majority of patients were MSM infected with subtype
B virus. Thus, we cannot exclude that the aspects of
HIV-1 evolution that we have investigated differ between
transmission routes or HIV-1 subtypes. While substitu-
tion and recombination errors of our optimized protocol
for HIV-1 RNA extraction and an RT PCR are low, the
other main limitation was the at times small number of
available template molecules that we quantified by limit-
ing dilution. In principle, the Primer ID method, which
labels and resequences each individual template, allows
quantification of templates and almost complete elimina-
tion of experimental substitution and recombination er-
rors (Jabara et al., 2011). However, we are not aware of
a Primer ID protocol for genome-wide sequencing which
was essential to our study.
HIV-1 and other microbial populations evolve in a con-
stant struggle between adaptation to a changing environ-
ment and maintenance of functionality. Large mutations
rates and population sizes generate standing genetic di-
versity that is limited by the fitness costs rather than
mutation rates. Hence the limiting factor for adapta-
tion is not generating the useful mutations, but combin-
ing multiple mutations necessary to survive – e.g. escape
mutations and reversions – and pruning deleterious mu-
tations. In HIV-1, this process is facilitated by frequent
recombination.
We expect that the systematic exploration of sequence
space, the reproducible patterns of minor variation, and
frequent reversion will be characteristic of other RNA
viruses. Properties of linkage between mutation will dif-
fer since mechanisms of recombination are diverse. But
even though selective forces, recombination, and time
scales will vary among different microbial populations,
theoretical models of rapid adaptation population have
shown that many features of the evolutionary dynamics
are independent of the specific system (Fisher, 2013; Ne-
her, 2013). Intrapatient evolution of HIV-1 is a unique
opportunity to study this evolutionary dynamics directly
in vivo.
Materials and Methods
Ethical statement
The study was carried out according to the Declara-
tion of Helsinki. Ethical approval was granted by the Re-
gional Ethical Review board in Stockholm, Sweden (Dnr
2012/505-31/12). Patients participating in the study
gave written and oral informed consent to participate.
9Patient selection and samples
The inclusion criteria for the study patients were: a) a
relatively well-defined time of infection based on a neg-
ative HIV antibody test less than two years before a
first positive test or a laboratory documented primary
HIV infection; b) no antiretroviral therapy (ART) for a
minimum of approximately five years following diagno-
sis; and c) availability of biobank plasma samples cov-
ering this time period. An additional inclusion criterion
was used to allow inclusion in an ongoing substudy; suc-
cessful ART (plasma viral levels <50 copies/µl) for a
minimum of two years after at least five years without
therapy. The patients were selected from the Venhälsan
HIV clinic in Stockholm, Sweden and were diagnosed be-
tween 1990 and 2003. Seven to twelve plasma samples
per patient (200 µl - 1000 µl) were retrieved from the
biobanks of the Karolinska University Hospital and the
Public Health Agency of Sweden. These samples had
been stored at -70◦C following routine HIV RNA quan-
tification. Information about the patients and the sam-
ples are summarized in Table S1 (S1_samples.csv). Re-
sults from routine HIV antibody tests, HIV antigen tests,
plasma HIV RNA levels and CD4 counts were collected
from the patient records. Four-digit HLA typing of HLA
class I loci A, B, C and class II loci DR and DQ was per-
formed at the Laboratory of Immunpathology, Tübingen
University Hospital.
In the control experiments we used HIV DNA from the
following plasmids; NL4-3 (subtype B, DNA concentra-
tion 110 ng/µl corresponding to 1.35 × 1010 copies/µl),
SF162 (subtype B, DNA concentration 117 ng/µl corre-
sponding to 1.43 × 1010 copies/µl), pZM246F_10 (sub-
type C, DNA concentration 101 ng/µl corresponding to
1.35× 109 copies/µl).
We also used HIV RNA from the following virus iso-
lates LAI III (subtype B, 7,500 copies/µl), 38540 (sub-
type C, 225,000 copies/µl) and 38304 (subtype B, 45,000
copies/µl).
Estimated time since infection (ETI)
The patients were classified according to the Fiebig
staging system for primary and early HIV infection
(Fiebig et al., 2003). In addition, we performed BED
tests (Awarer BEDr EIA HIV-1 Incidence Test, Calypte
Biomedical Corporation, Portland, OR, USA). For each
patient the date of infection was estimated using results
from laboratory tests according to the following hierar-
chical scheme.
1. Fiebig staging (Fiebig et al., 2003) was used if re-
sults on HIV RNA, antigen, EIA and Western blot
were available and the patient found to be in Fiebig
stage I-V. Fiebig stages I-VI were considered to cor-
respond to 13, 18, 22, 27, 65 and >100 days since
infection based on Cohen et al. (2011). This was
applicable to patients no. 1, 2, 6, 8 and 10.
2. For patients in Fiebig stage VI or with unclear
Fiebig stage, ETI was considered to be midpoint
between the dates for last negative and the first
positive HIV tests if the time interval between these
tests was <1 year. This was applicable to patient
no. 5.
3. For remaining patients ETI was calculated using a
published time-continuous model of development of
antibodies reactive in the BED assay (Skar et al.,
2013). However, ETI was not considered to be
<100 days for patients in Fiebig stage VI. This was
applicable to patients no. 3, 9 and 11.
Primer design
Primers were designed to cover almost the full HIV
genome in six overlapping fragments, called fragments
F1-F6 as illustrated in Figure 1. This allowed sequencing
of nucleotide positions 571 to 9567 in the HxB2 reference
sequence according to the Sequence Locator Tool avail-
able at www.hiv.lanl.gov. Because of the redundancy
of the long terminal repeats (LTRs) this means that all
genomic regions except positions 482-571 in the R region
of the LTRs were sequenced. Primer design was per-
formed using the subtype reference alignment and the
PrimerDesign software available at www.hiv.lanl.gov
(Brodin et al., 2013). PrimerDesign was used to find
candidate forward and reverse primers targeting highly
conserved regions of the HIV genome, with similar melt-
ing temperatures, and with minimal tendency for hairpin
and primer-dimer formation. Candidate primers were
manually adjusted if needed, tested and sometimes re-
designed. For each genome fragment both outer PCR
primers and nested, inner primers were designed; inner
primers were only used for template quantification and
internal testing purposes. Alternative primer sets were
created for genome fragments F3 and F5 because the
PCRs with the original primers sometimes were ineffi-
cient. For fragment F5 the amplification problem was
not completely alleviated despite trials with several dif-
ferent primer pairs. We believe that this might be be
due to the extensive secondary structere in the RRE re-
gion. The primers are presented in supplementary table
S2 (S2_primer_list.pdf). All primer positions except
the 5’ primer of F1 and the 3’ primer of F6 are con-
tained in neighboring amplicons and hence sequenced. Of
course, the primer part of the reads itself was trimmed
after sequencing (see below).
RNA extraction and amplification
For each sample, 400 µl of plasma (if available) was
divided into two 200 µl aliquots. Total RNA was ex-
tracted using RNeasyr Lipid Tissue Mini Kit (Qiagen
Cat. No. 74804). Each aliquot was eluted twice with 50
µl RNase free water to maximize HIV RNA recovery. The
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four eluates were pooled giving a total volume of 200 µl of
RNA per sample. The RNA was divided into twelve 14 µl
aliquots for duplicate one-step RT-PCR with the outer
primers for fragments F1 to F6 and Superscript r III
One-Step RT-PCR with Platinum r Taq High Fidelity
Enzyme Mix (Invitrogen, Carlsbad, California, US).
Remaining RNA was used for template quantification
(see below). The one-step RT-PCR was started with
cDNA synthesis at 50◦C for 30 min and denaturation
step at 94◦C for 2 min followed by 30 PCR cycles of de-
naturation at 94◦C for 15 sec, annealing at 50◦C for 30
sec and extension at 68◦C for 90 sec and a final extension
step at 68◦C for 5 min. A second nested PCR was used
for template quantification and in some of the control
experiments. For the second PCR, 2.5 µl of the prod-
uct from the first PCR was amplified with Platinum Taq
High Fidelity. The second PCR consisted of a denatura-
tion step at 94 ◦C for 2 min, followed by 30 PCR cycles
with denaturation at 94◦C for 15 sec, annealing at 50◦C
for 20 sec and extension at 72◦C for 90 sec and a final
extension at 72◦C for 6 min. Other PCR conditions were
also tried during assay development.
After PCR, the duplicate amplicons from each of the
six overlapping PCRs were pooled and purified with Il-
lustra™ GFX™ PCR DNA and Gel Band Purification Kit
(28-9034-70, VWR) or AGENCOURT™ AMPure™ XP
PCR purification kit (A63881, Beckman Coulter AB).
Purified amplicons from each sample were quantified with
Qubit™ assays (Q32851, Life Technologies) and there-
after diluted and pooled in equimolar concentrations.
DNA library preparation
The Illumina Nextera XT library preparation protocol
and kit were used to produce DNA libraries. The origi-
nal protocol was optimized for longer reads and amplicon
input in the following fashion: (i) Input DNA concentra-
tion to tagmentation was increased to 0.3 ng/µl to reduce
overtagmentation; (ii) The number of post-tagmentation
PCR cycles was raised up to 14 for samples with very
low input DNA; (iii) Post-PCR purification was done us-
ing Qiagen Qiaquick columns to maximize large-inserts
throughput as compared to magnetic-bead based proto-
cols; (iv) Size selection was performed using the Sage-
Science BluePippin system with 1.5% agarose gel cas-
settes and internal marker R2, selecting sizes of 550 to
900 bp (including dual index Nextera adapters, final in-
sert sizes 400 bp to 700 bp); (v) Size-selected eluates were
pooled, buffer-exchanged into EB (10 mM Tris-HCl), and
reconcentrated to at least 2 nM.
Sequencing
The Illumina MiSeq instrument with 2× 250bp or 2×
300bp sequencing kits (MS-102-2003/MS-102-3003) was
used to sequence the DNA libraries. We performed 26
paired-end sequencing runs. Overall, we obtained around
200 Gbases of output, i.e. 300 Mbases for each PCR
amplicon. The median number of reads per amplicon
was 80,000 (quartiles 20,000-220,000, max 2 millions).
All read files have been uploaded to ENA with study
accession number PRJEB9618.
Read mapping and filtering
Bases were called from the raw images using Casava
1.8. The reads were analyzed from that point on using a
custom pipeline written in Python 2.7 and C++. We fa-
vored this pipeline over existing programs because HIV-1
is a diverse species and both coverage and genetic di-
versity typically fluctuate by many orders of magnitude
across the genome. The pipeline works as follows: (i)
reads were mapped onto the HIV-1 reference HxB2, us-
ing the probabilistic mapper Stampy (Lunter and Good-
son, 2011); (ii) mapped reads were classified into one of
the six overlapping fragments used for RT-PCR (ambigu-
ous and chimeric reads were discarded), and trimmed
for PHRED quality above or equal 30 except for one
isolated position per read; RT-PCR primers were also
trimmed at this step; (iii) a consensus sequence was com-
puted for each fragment in each sample from a subset
of the reads, using a chain of overlapping local multi-
ple sequence alignments (each covering around 150 bp);
(iv) the reads were re-mapped, this time against their
own consensus; (vii) genetic distance from the consen-
sus were computed, and reads with a distance higher
than a sample- and fragment-specific threshold were dis-
carded. Each threshold, calculated to exclude even traces
of cross-contamination that might have happened during
RNA extraction, PCR amplification, or library prepa-
ration, was established by plotting the distribution of
Hamming distances of reads from the sample consensus,
and excluding reads that are further away than the tail
of the main peak. Contaminations appeared as a sec-
ond peak at higher distances, recombinants as a fat tail:
both were excluded. Reads were also trimmed for map-
ping errors at the edges (small indels); (viii) filtered reads
were mapped a third time against a patient-specific ref-
erence that was as similar as possible to the consensus
sequence from the earliest time point; (ix) reads were re-
filtered and checked again for cross-contamination. The
pipeline was equipped with extensive consistency checks
for base quality, mapping errors, and contamination, and
is based on the open source projects numpy (van der Walt
et al., 2011), matplotlib (Hunter, 2007), Biopython (Cock
et al., 2009), samtools (Li et al., 2009), pandas (McKin-
ney, 2011), and SeqAn (Döring et al., 2008).
Quality controls
PCR and sequencing errors We added 1-5% of PhiX con-
trol DNA to all our sequencing runs. Comparison of reads
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that mapped to PhiX with the PhiX reference sequence
revealed that the Phred quality score were a rather re-
liable indicator of error rates, with saturation around
0.1%. SNP calls were calculated from the reads using a
custom pile-up restricted to reads with a PHRED quality
>= 30 corresponding to a minimal theoretical error rate
of 0.1% per base. However, in a dedicated set of control
experiments, we established that the main source of error
is PCR, see Figure 1 in the main text.
We estimated the error rate of the PCR and sequenc-
ing pipeline by amplifying and sequencing plasmid clones
(NL4-3, SF162, LAI-III). In most of these experiments we
used 104 template molecules. The distribution of single
nucleotide polymorphism(SNP) frequencies found in the
sequencing reads generated from the plasmid were com-
pared to sequencing results from a typical patient sample,
see Figure 1. After quality filtering, PCR and sequencing
errors never exceed 0.3% of reads covering a particular
position. Hence SNPs found in more than 0.3% of all
reads likely represent biological variation. Note that this
neither implies that we detect all biological variants at
frequencies above 0.3%, nor does the frequency of a SNP
among the reads necessarily reflect the frequency of that
SNP in the sample. For many samples the detection limit
and accuracy of quantification of minor variants was not
limited by the sequencing error, but by the RNA tem-
plate input and potential PCR bias.
Template input To roughly quantify the actual number
of HIV RNA templates that were subjected to sequenc-
ing, we analyzed a dilution series of the RNA (1:10,
1:100, 1:1,000, and 1:10,000) with the nested primers for
fragment F4 using the PCR conditions described above.
Tests were done in duplicate on the same plate as ampli-
fications for sequencing and the amplicons were visual-
ized by agarose gel electrophoresis. Templates numbers
were estimated based on the assumption of Poisson sam-
pling. Thus, for each sample, this dilution series pro-
vides an estimate of the number of templates that make
it into the sequencing library. The results from the limit-
ing dilution experiments correlated well (rank correlation
ρ = 0.7) with routine plasma HIV-1 RNA level measure-
ments that had been performed at time of sampling, see
Figure 9. These comparisons showed that the median
template cDNA recovery efficiency was 30% (quartiles
17% – 60%), which should be regarded as satisfactory
since the amplicons were relatively long and the samples
had been stored for up to 24 years and sometimes also
freeze-thawed prior to this study.
PCR bias In addition to quantification of template input
for each sample, we separately estimated the recovery of
sequence variation in each of the six sequenced ampli-
cons. Adjacent fragments overlap each other by a few
hundred bases. Variation in the overlapping regions is
amplified and sequenced on both the leading and trailing
fragment completely independently and the concordance
of the observed variant frequencies, see Figure 9, can be
used to detect PCR amplification bias or poor recovery
in a subset of the fragments.
If deviations of SNP frequencies are due to random
sampling from the pool of RNA molecules and stochas-
tic PCR efficiency, the variance between the frequen-
cies observed on two neighboring fragments should be
x(1 − x)(n−1L + n−1T ), where x is the true frequency of
the SNP. The numbers nL and nT correspond to effec-
tive template numbers specific to leading (L) and trailing
(T ) fragment. For each SNP in the overlap, we calculate
the difference δ and the mean x of the frequencies re-
ported on the L/T fragment. An estimate of n−1L + n
−1
T
is then given by
1
k + p
[
k∑
i
δ2i
x(1− x) +
p
ndil
]
, (1)
where k is the number of SNPs in the overlap. To increase
robustness of this estimate, we include p pseudo counts
each of which contributes n−1dil , where ndil is the template
number estimated from the dilution series. Since we have
6 fragments but (in the best case) only 5 overlaps, the
effective fragment template numbers are not uniquely de-
termined. However, their inverse has to be smaller than
the minimum of the estimate of n−1L + n
−1
T at any over-
lap the fragment participates in. We hence assign a lower
bound for the fragment specific template estimate by us-
ing the inverse of this minimum, provided with find at
least k = 5 SNPs in the overlap at an average frequency
above 0.03. We use p = 3. Changing the parameters
doesn’t change the numbers qualitatively.
The fragment specific estimates of template numbers
are consistent with the estimates based on limiting dilu-
tion (see Figure 9, rank correlation around ρ = 0.5 for
most of the fragments), but indicated that variant recov-
ery in fragment F5 was sometimes poor, consistent with
the difficulties we encountered when amplifying fragment
F5. Furthermore, the agreement of SNP frequencies in
the overlaps indicate that the primers were well-designed
and did not induce significant primer-related PCR am-
plification biases. These fragment specific estimates are
only available for samples and fragments with sufficient
diversity in the overlap regions and are often lacking for
early samples and fragment F6. The latter is due to the
very conserved overlap with fragment F5.
Taken together, these controls show that depending
on the sample and fragment, we can estimate frequen-
cies of SNPs down to 1% accuracy (corresponding to sev-
eral thousand effective templates). In some cases, how-
ever, the template number was low or recovery poor such
that no more than presence absence of a variant could
be called. All fragment available specific estimates are
shown in Figure 9B. In addition to lack of concordance
of SNP frequencies in overlaps, problematic fragments
lack diversity or have a granular distribution of SNP fre-
quencies such that they can be flagged and removed from
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specific analysis. The fact that PCR efficiency can vary
within one sample is illustrated in Figure 9 – supplement
1 that compares SNP frequencies estimated in samples
4 and 5 of patient 1 that are only 30 days apart: While
SNP frequencies agree to within expectation for 5 out of
6 fragment, fragment F5 shows strong deviations linked
to suboptimal PCR efficiency. However, even in problem-
atic samples our amplification and sequencing approach
does not generate spurious variation, as shown by the ab-
sence of diversity in early samples or conserved sites (see
below).
In vitro recombination and linkage The paired-end reads
obtained correspond to inserts of up to 700bp in length
and therefore provide information on linkage of muta-
tions up to that distance. However, cDNA synthesis and
PCR have both the potential to generate in vitro recom-
bination, and true biological linkage is preserved only if
the frequency of in vitro recombination is low. To es-
timate the in vitro recombination in our experimental
setup, virions from two subtype B HIV isolates, LAI III
and 38304 (the latter obtained from a Swedish HIV-1 pa-
tient infected in Brazil), were mixed in equal concentra-
tions. Aliquots of this mix (approximately 1,250 RNA
molecules per PCR fragment) were amplified with the
six overlapping one-step RT-PCRs as described above in
both single PCR and nested PCR mode and then se-
quenced.
PCR recombination is known to occur predominantly
at high amplicon concentrations due to hetero duplex
formation of incompletely extended molecules (Di Gial-
lonardo et al., 2013; Mild et al., 2011)). Consistently,
we observe no PCR recombination within the first PCR
(which starting at low template input does not saturate),
while we observe substantial PCR recombination dur-
ing a second nested PCR. Since our library preparation
protocol requires very low input DNA, we do not need
nested PCR, avoiding this source of PCR recombination.
The fact that PCR recombination occurs during a sec-
ond PCR shows that the two viruses used for this con-
trol (both subtype B) are similar enough that divergence
does not interfere with heteroduplex formation. Figure 7
includes the linkage disequilibrium observed in the con-
trol experiment as a function of distance, showing that
linkage is high and not lost with distance during the first
PCR.
Analysis
Python scripts that generate each figure shown in
the manuscript are available at github.com/neherlab/
HIVEVO_figures. In these scripts, all parameters, set-
tings, and calculations are explicitly documented.
Divergence and diversity: Average divergence defined as
the fraction of non-founder alleles in a sliding window
of 300bp was regressed against the estimated times since
infection using a linear model without intercept. Differ-
ent data points were weighted by the total divergence,
reflecting the expected scaling of the variance if diver-
gence is due to changes at many independent sites. The
evolutionary rate was than mapped to the corresponding
coordinate in the HxB2 reference.
Phylogenetic analysis: To construct trees in different re-
gions of the HIV-1 genome, we extracted reads covering
the desired region, restricted them to haplotypes above
the desired frequency threshold and constructed a max-
imum likelihood phylogeny using FastTree (Price et al.,
2009). Trees were rooted at the consensus sequence of
the earliest available sample.
Linkage disequilibrium: To calculate linkage disequilib-
rium, we first constructed four dimensional matrices for
each fragment and each sample, that report the num-
ber of times reads mapped such that a nucleotide n1 at
position x1 was jointly observed with nucleotide n2 at
position x2. From these matrices, we calculate the joint
frequency p12(x1, x2) of the majority nucleotide at po-
sitions (x1, x2). The normalized linkage disequilibrium
measure is then given by
D′ =
|p12 − p1p2|
Dmax
(2)
where p1, p2 are the frequencies of the majority nucleotide
at the respective positions, and
Dmax =
{
min(p1p2, (1− p1)(1− p2)) p12 < p1p2
min(p1(1− p2), (1− p1)p2) p12 > p1p2
Values of D′ are then binned by distance and plotted.
To reduce noise, only SNPs at frequencies between 20
and 80% at positions with a coverage > 200 were in-
cluded. Furthermore, we required that the fragment spe-
cific depth estimate exceeded 40 or the estimated tem-
plate input exceeded 200. The latter is necessary to in-
clude fragment F6, since the overlap with fragment 5
often had in-sufficient diversity to allow for a fragment-
specific depth estimate.
Diversity and divergence Synonymous and non-
synonymous divergence was analyzed on a per site
basis to avoid confounding by different number of
transitions and transversions. Positions were classified
as synonymous based on the following criterion: The
consensus amino acid at this position did not change
throughout infection and at least the transition at this
site is synonymous. In this case, the observed mutations
at this site are almost always synonymous.
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Figure 9 Template quantification and accuracy of SNP frequency estimates. The left panel shows actual template
numbers as experimentally determined by end point dilution (y-axis) vs the maximum theoretical template input as estimated
based on plasma virus levels. The estimates from the dilutions are typically a factor of three below the expectation from
viral load, suggesting generally good template recovery. The center panel show the correlation of fragment specific effective
template numbers estimated from the concordance of SNPs in fragment overlaps. Again, the correlation is generally good, but
fragment F5 often has estimates lower than those from the dilution series consistent with problems faced in amplification of
this fragment. Information from fragment F6 is largely absent, since there is very little variation in the F5-F6 overlap. The
right panel plots SNP frequencies in overlaps measured in the leading fragment against the trailing fragment. Deviations from
the diagonal are due PCR bias and random sampling from limited template molecules. Given enough diversity in overlap
regions, the concordance of variant frequencies can be used to estimate fragment specific template input and accuracy of SNP
frequencies.
The functional categories for genomic regions were the
following: structural: p17, p24, p6, p7; enzymes: pro-
tease, RT, p15, integrase; accessory: vif, vpu, vpr, nef;
envelope: gp120 and gp41. For the CTL epitope predic-
tion, ranked epitope lists were obtained using the web
service MHCi (tools.immuneepitope.org/mhci). This
tool uses several prediction methods ranked based on
previously observed performance: Consensus (Moutaftsi
et al., 2006) > Artificial Neural Network (Nielsen et al.,
2003) > Stabilized Matrix Method (Peters and Sette,
2005) > NetMHCpan (Hoof et al., 2008). For each pa-
tient, we submitted the consensus amino acid sequences
of the viral proteins at the first time point together with
4-digit HLA types at MHC-I. To analyze putative CTL
escape in our patients, we used the first 80 epitopes from
the ranked list as a compromise between false negatives
and false positives. This number maximized the statis-
tical signature for HIV-1 substitutions being within epi-
topes, but similar results were obtained by taking the
first 50-100 epitopes in the lists.
We preferred computational predictions over experi-
mentally verified CTL epitopes, since the latter are in-
complete and biased towards common virus sequences
and HLA types. For each patient, we submitted the ap-
proximate founder sequence (consensus sequence of the
first sample) to MHCi and obtained a list of peptides
putatively presented by the HLA alleles (A/B/C) of the
respective host ranked by prediction score.
We considered the parts of the HIV-1 genome that pu-
tatively is targeted in any of the nine patients, and asked
whether the density of nonsynonymous substitutions is
higher in the part that is predicted to be presented in a
focal patient compared to the part that is not presented.
We excluded the variable loops of gp120 and the exter-
nal part of gp41 from this analysis to avoid confounding
by antibody selection. Repeating the same analysis for
synonymous mutations did not yield any enrichment as
expected. The results are insensitive to the number of
predicted epitopes used.
Comparison with subtype diversity Full genome HIV-
1/SIVcpz sequences were downloaded from LANL HIV
data base. Sequences belonging to subtypes B, C, and
01_AE were individually aligned to HxB2 (using pair-
wise alignment functions from SeqAn (Döring et al.,
2008)) to construct a summary of diversity within sub-
types in HxB2 coordinates. Similarly, a group M di-
versity summary in HxB2 coordinates with made from
sequences of subtypes A, B, C, D, F, G, H, restricted
to at most 50 sequences from any given subtype. From
these HxB2 indexed alignments, entropy was calculated
columnwise and the consensus sequence determined as
the majority nucleotide.
When comparing HIV variation within patients to
cross-sectional diversity, only positions of the founder se-
quence were used that mapped to HxB2. Similarly, only
positions in the cross-sectional alignment were used that
had less than 5% gaps relative to HxB2. This effectively
masked regions of the genome that frequently experience
insertions of deletions.
To investigate divergence and reversion, intrapatient
evolution was studied separately at sites where the ap-
proximate founder sequence agreed/disagreed with the
respective subtype or group M consensus. Divergence
was assessed on a per site basis.
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